Biogen Idec News
-
Updated 11 minutes ago
Alex Denner, the former head of health-care investments for billionaire Carl Icahn, joined the activist slate challenging drugmaker Vivus Inc. in the first move of his new fund, Sarissa Capital Management LP.
-
Teva Pharmaceutical Industries Ltd., which just two years ago was analysts’ highest-rated stock among the world’s 20 biggest drugmakers, is struggling to convince investors that a key part of its strategy will revive growth.
-
Royalty Pharma, an investor in royalty streams from pharmaceuticals, raised its offer to buy Elan Corp. by 12 percent to $6.4 billion after the Irish drugmaker made acquisitions to boost revenue and resist the bid.
-
Roche Holding AG’s experimental leukemia drug shrank tumors in more patients when added to chemotherapy, according to study results that may aid the company in expanding its line of blood-cancer treatments.
-
Elan Corp. agreed to pay $1 billion for a share of the royalties on new drugs from Theravance Inc. as the Irish drugmaker tries to persuade shareholders to spurn a takeover offer by Royalty Pharma.
-
Teva Pharmaceutical Industries Ltd.’s first-quarter profit fell 26 percent as a branded drug lost patent protection and opportunities diminished to introduce new generic medicines.
-
The introduction of Biogen Idec Inc.’s multiple sclerosis pill, Tecfidera, outstripped the initial sales of competing drugs from Novartis AG and Sanofi, suggesting the treatment may beat estimates for the year.
-
Biogen Idec Inc., the fourth- largest U.S. biotechnology company by market value, reported first-quarter net income rose 41 percent on higher sales of its multiple sclerosis drugs.
-
Biogen Idec Inc., the fourth- largest U.S. biotechnology company by market value, raised its full-year forecast after first-quarter net income increased on a tax benefit.
-
Bayer AG’s patent on the birth control pill Yaz is invalid, a U.S. appeals court said in a decision ensuring that Actavis Inc. and Novartis AG’s Sandoz unit can sell copies of the contraceptive.
|
|
Most Popular on Bloomberg
|
| |
Rate this Page